Drug
Selicrelumab clinical trials
Also written CP-870,893 and RO7009789.
- studies test it
- 11
- open now
- 1
- in phase 3
- 0
- first study started
- 2004
Keep track of what changes. Save the selicrelumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Other names
Studies by the year they started
11 studies that test it; most in 2018 (2)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2012 | 1 |
| 2014 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 10
- Phase 2
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 6
Hoffmann-La Roche (5) · Abramson Cancer Center at Penn Medicine (4) · H. Lee Moffitt Cancer Center and Research Institute (1) · The Lymphoma Academic Research Organisation (1)
Often tested with
Tested in the same studies.
Atezolizumab (5) · Bevacizumab (3) · Albumin-Bound Paclitaxel (2) · Paclitaxel (2) · AB928 (2) · Tocilizumab (2) · Gemcitabine (1) · Cobimetinib (1)
Studies
Open first, then newest update. How each study uses selicrelumab is read from its arms, and is right about nine times in ten.
Testing it · 11
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerRecruitingPhase 1/2Hoffmann-La RocheNCT03424005Written as Selicrelumab
- A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)CompletedPhase 1/2Hoffmann-La RocheNCT03193190Written as Selicrelumab
- A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)TerminatedPhase 1/2Hoffmann-La RocheNCT03555149Written as Selicrelumab
- Study of Intratumoral Selicrelumab With Atezolizumab in Patients With Refractory or Relapsed B Cell LymphomaTerminatedPhase 1The Lymphoma Academic Research OrganisationNCT03892525Written as Selicrelumab
- Tremelimumab and CP-870,893 in Patients With Metastatic MelanomaCompletedPhase 1Abramson Cancer Center at Penn MedicineNCT01103635Written as CD40 agonist monoclonal antibody CP-870,893
- A Study of Selicrelumab (RO7009789) in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid TumorsCompletedPhase 1Hoffmann-La RocheNCT02304393Written as Selicrelumab
- Phase 1, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid TumorsCompletedPhase 1Abramson Cancer Center at Penn MedicineNCT02225002Written as CP-870,893
- Phase 1 Study of Preoperative Gemcitabine Plus CP-870, 893 Followed by Addition of CP-870,893 to Standard -Of-care Adjuvant Chemoradiation for Patients With Newly Diagnosed Resectable Pancreatic CarcinomaCompletedPhase 1Abramson Cancer Center at Penn MedicineNCT01456585Written as CP-870,893
- Redosing With CP-870, 893 in Patients With Clinical Benefit After a Single Infusion From A Phase I, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid TumorsCompletedEarly Phase 1Abramson Cancer Center at Penn MedicineNCT02157831Written as CP-870,893
- A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid TumorsCompletedPhase 1Hoffmann-La RocheNCT02760797Written as RO7009789
- Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100CompletedPhase 1H. Lee Moffitt Cancer Center and Research InstituteNCT01008527Written as CP 870,893
Given in every arm · 1 — selicrelumab is usual care beside what is tested
Codes
What other systems call selicrelumab · ClinicalTrials.gg INT005051
- MeSH (NLM) C518149selicrelumabOne source NLM
- UNII (FDA) 0O39RGI33VSELICRELUMABConfirmed FDA, NLM
- NCI Thesaurus C119740SelicrelumabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C518149 | selicrelumab | One source NLM |
| UNII (FDA) | 0O39RGI33V | SELICRELUMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C119740 | Selicrelumab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.